Comparative Pharmacology
Head-to-head clinical analysis: ALPHAGAN versus TIZANIDINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHAGAN versus TIZANIDINE HYDROCHLORIDE.
ALPHAGAN vs TIZANIDINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Tizanidine is a centrally acting alpha2-adrenergic agonist that reduces spasticity by increasing presynaptic inhibition of motor neurons. It binds to alpha2-adrenergic receptors in the spinal cord and brain, inhibiting excitatory neurotransmitter release (e.g., glutamate, aspartate) and facilitating glycinergic inhibition.
1 drop of 0.1% or 0.15% solution in the affected eye(s) three times daily, approximately 8 hours apart.
Initial: 2 mg orally every 6-8 hours as needed; may increase by 2-4 mg per dose up to a maximum of 36 mg/day. Usual maintenance: 2-4 mg three times daily.
None Documented
None Documented
2.5-3.0 hours in adults; in renal impairment, half-life is prolonged (up to 6 hours).
Terminal elimination half-life is approximately 2.5 hours (range 2–4 hours). In patients with renal impairment (CrCl <25 mL/min), half-life may be prolonged up to 14 hours due to reduced clearance.
Renal: approximately 70-80% as unchanged drug and metabolites; fecal: 5-10%.
Approximately 60% of the dose is excreted in urine (mainly as metabolites, <5% unchanged) and 20% in feces. Renal clearance accounts for the majority of elimination, with a renal clearance of about 2 L/h.
Category C
Category A/B
Alpha-2 Agonist
Alpha-2 Agonist